Chicago

Microfluidic Device Platform for Perfusion Chamber Systems

ElectronicsDiagnostic biological tests/assays

In stroke research, the hippocampal acute brain slice preparation is a model for studying how neuronal tissue responds to a hypoxic insult. Additionally, in diabetes research, pancreatic islets preparation and dynamic loading of oxygen and glucose is critical to understand how hypoxia alters the glucose-insulin response of the pancreas. However, standard techniques using commercial perfusion chambers cannot accurately provide oxygen delivery and control to model hypoxic conditions.

EnterpriseWorks Chicago - SBIR/STTR Webinar Series: QuickBooks and Compliance for SBIR/STTR Recipients

Date: 
06/06/2013 - 12:00pm - 1:00pm

Learn how to manage your SBIR/STTR grant or contract to improve your odds of moving from Phase I to Phase II, and Phase II to Phase III (transition and/or commercialization). Kris will review the various sources for managing funds from DoD, NIH, NSF, or DoE, as well as reporting requirements and close-out procedures.  Attendees will also learn how to use QuickBooks accounting software to manage accounting requirements.

EnterpriseWorks Chicago - SBIR/STTR Webinar Series: How to Prepare a Budget for SBIR/STTR Proposals

Date: 
05/16/2013 - 12:00pm - 1:00pm

This session walks through the development of a project budget. It covers what costs need to be included, how to write a budget justification, assessing whether your company can afford to pursue the project, what indirect rate should be used and more. 

Translation Research and Who To Look To for Help

Date: 
05/07/2013 - 1:30pm - 5:30pm

 

Save the Date for an informational speaking engagement and reception on May 7, 2013 at the Moss Auditorium in COMRB. Co-hosted by the Office of Technology Management, UICentre, the UIC Cancer Center and UIC Center for Clinical and Translational Science, this event looks to assist in pointing researcherstoward the rightresources that can help to advance their research efforts. The agenda for the event is as follows:

 

1:30-2:30 UICentre Overview and Services

2:30-3:00 Cancer Center Overview and Services

3:00-3:15 Break

Chicago Drug Discovery Consortium

Date: 
05/23/2013 - 8:30am

 

Click here to register

To view the full program click this link...CDDC- Program.pdf

Nexturastat, a novel Urea-based HDAC6 inhibitor effective against specific cancers

Therapeutic

Histone deacetylases (HDACs) mediate regulation of gene expression via changes in nucleosome conformation.  Dysregulation of histone acetylation, can lead to the development of cancers. There is renewed interest in capitalizing new breakthroughs in epigenetic research to address oncology therapy. Epigenetic regulation and subsequent gene expression or silencing represents a tightly orchestrated interplay among enzymes responsible for modifying the tails of histones, around which nuclear DNA is wrapped.

Novel Isoxazole-Based HDAC6 Selective Inhibitors for the Treatment of Charcott-Marie-Tooth (CMT), a new epigenetic approach to therapy

Therapeutic

Histone deacetylases (HDACs) mediate regulation of gene expression via changes in nucleosome conformation.  Dysregulation of histone acetylation, involving CBP, a neuroprotective transcription factor with histone acetyltransferase activity, has been found in Huntington’s disease (HD), Alzheimer’s disease (AD), and Rubinstein-Taybi syndrome. In a cellular model of AD, cell death was accompanied by loss of CBP function and histone deacetylation. 

"Drug Discovery from Target Selection to Clinical Trials: How Can the CCTS, UICentre and NIH Help?"

Date: 
04/02/2013 - 12:00pm - 1:00pm

CCTS PROFESSIONAL DEVELOPMENT WORKSHOP SERIES

*Sponsored by the CCTS Research Education and Health Careers (REACH) Program and the UICentre for Drug Discovery 

Carbazole Derivatives as G9a Methyltransferase Inhibitors for Cancer Treatment and Autophagy Induction.

Therapeutic

G9a is overexpressed in various human cancer including leukemia, prostate cancer, hepatocellular carcinoma and lung cancer. Inhibitors of G9a are candidates for cancer treatment. A new family of G9A inhibitors have been recently identified and characterized. Through the characterization of these inhibitors, insight has been gained on the mechanistic contribution of G9a in the deregulation of the cell cycle in cancer and methyltransferase G9a regulation of a crucial step in cellular degradation.

print